CHAMPIX TABLET STARTER PACK [SIN13322P]

Product Info

CHAMPIX TABLET STARTER PACK

[SIN13322P]

4.1 Therapeutic indications

CHAMPIX is indicated as an aid to smoking cessation treatment.

4.2 Posology and method of administration

Usual Dosage for Adults

Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt.

The patient should set a date to stop smoking. CHAMPIX dosing should start one week before this date. Alternatively, the patient can begin CHAMPIX dosing and then quit smoking between days 8 and 35 of treatment (see section 5.1 Pharmacodynamic properties – Flexibility in Setting a Quit Date – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

The recommended dose of CHAMPIX is 1 mg twice daily following a 1-week titration as follows:

Patients should be treated with CHAMPIX for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with CHAMPIX at 1 mg twice daily is recommended for the maintenance of abstinence (see section 5.1 Pharmacodynamic properties – Maintenance of Abstinence Study – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

A gradual approach to quitting smoking with CHAMPIX should be considered for patients who are not able or willing to quit abruptly. Patients should reduce smoking during the first 12 weeks of treatment and quit by the end of that treatment period. Patients should then continue taking CHAMPIX for an additional 12 weeks for a total of 24 weeks of treatment (see section 5.1 Pharmacodynamic properties – Gradual approach to quitting smoking – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed (see section 5.1 Pharmacodynamic properties – Study in Subjects Re-treated with CHAMPIX – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Patients who cannot tolerate adverse effects of CHAMPIX may have the dose lowered temporarily or permanently.

CHAMPIX tablets should be swallowed whole with water. CHAMPIX can be taken with or without food.

Patients with renal insufficiency

No dosage adjustment is necessary for patients with mild to moderate renal impairment. For patients with severe renal impairment, dosing should begin at 0.5 mg once daily for the first 3 days then increased to 1 mg once daily. There is insufficient clinical experience with varenicline in patients with end stage renal disease (see section 5.2 Pharmacokinetic properties – Patients with renal insufficiency – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Patients with hepatic impairment

No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2 Pharmacokinetic properties – Patients with hepatic impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Use in elderly patients

No dosage adjustment is necessary for elderly patients. Because elderly patients are more likely to have decreased renal function, prescribers should consider the renal status of an elderly patient (see above Patients with renal insufficiency and section 5.2 Pharmacokinetic properties – Patients with renal insufficiency and Use in elderly patients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Use in pediatric patients

Safety and effectiveness of CHAMPIX in pediatric patients have not been established; therefore, CHAMPIX is not recommended for use in patients under 18 years of age.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.